AbbVie Presents P-III (Measure Up 1), (Measure Up 2) and (AD Up) Studies Results of Rinvoq for Atopic Dermatitis at 32nd EADV Congress 2023
Shots:
- The P-III studies evaluating Rinvoq in adults & adolescents aged ≥12yrs. through 140wks. In all P-III studies, patients treated with upadacitinib (15 or 30 mg) achieved the co-1EPs of improvement in skin clearance measured by an EASI 75 & vIGA-AD 0/1 at 16wk. vs PBO
- Patients achieved the 2EPs of improvement in skin clearance measured by EASI 90 & an additional EPs of itch reduction (WP-NRS 0/1). The efficacy was consistently maintained across all 3 studies
- In (Measure Up 1), (Measure Up 2) & (AD Up) studies, EASI 75 in upadacitinib (15 or 30 mg) were (88.8% or 90.3%), (82.0% or 90.7%) & (81.5% or 90.0%); vIGA-AD 0/1 (63.4% or 65.5%), (49.2% or 63.2%) & (52.0% or 56.8%); EASI 90 (70.7% or 73.8%), (63.5% or 77.5%) & (60.0% or 67.2%); WP-NRS ≥4 (68.0% or 70.5%), (61.4% or 71.4%) & (63.9% or 75.2%); WP-NRS 0/1 (46.8% or 50.2%), (43.2% or 52.5%) & (43.9% or 50.0%)
Ref: PR Newswire | Image: Abbvie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
